Bio-Techne’s fourth quarter was defined by flat revenue performance, yet the company exceeded Wall Street’s expectations on both top and bottom lines, prompting a positive market response. Management ...

Although Bio-Techne has underperformed the broader market over the past 52 weeks, Wall Street analysts maintain a moderately ...

Dr. Matt McManus to transition from his role as President, Diagnostics and Spatial Biology Segment, effective March 1, 2026 Steve Crouse, Senior Vice President of ...

Bio-Techne Corporation (NASDAQ:TECH) Q2 2026 Earnings Call Transcript February 4, 2026 Bio-Techne Corporation beats earnings ...

Bio-Techne Corp. closed 11.77% below its 52-week high of $75.69, which the company achieved on February 7th.

Detailed price information for Bio-Techne Corp (TECH-Q) from The Globe and Mail including charting and trades.

Shares of Charles River Laboratories International Inc. shed 8.42% to $165.98 Wednesday, on what proved to be an all-around mixed trading session for the stock market, with the S&P 500 Index remaining ...

Plus500 reports a transformative investment landscape with AI, quantum computing, and clean tech showing significant growth, ...

Detailed price information for Bio-Techne Corp (TECH-Q) from The Globe and Mail including charting and trades.

The global spatial biology market is projected to grow at a compound annual growth rate (CAGR) of approximately 15% over the ...